Vita Therapeutics Raises $32M in Series A Financing
Summary
Vita Therapeutics, a Baltimore, Md.-based cell engineering company harnessing the power of genetics to develop cellular therapies that follow an autologous and universal hypoimmunogenic approach, raised $32m in Series A funding. The round was led by Cambrian Biopharma with participation from Kiwoom Bio, SCM Life Sciences, and Early Light Ventures. In conjunction with the funding, James Peyer, PhD., Chief Executive Officer of Cambrian Biopharma, joined as newly appointed board member of Vita. Originally founded out of the labs of Dr. Gabsang Lee and Dr. Kathryn Wagner at Johns Hopkins University and the Kennedy Krieger Institute in 2019 by Douglas Falk, M.S. Its second therapeutic, VTA-200, is a genetically engineered iPSC derived hypoimmunogenic treatment designed to treat multiple types of muscular dystrophy.